CSIMarket
 
Bio path Holdings inc   (BPTH)
Other Ticker:  
 
 
Price: $4.6000 $-0.74 -13.777%
Day's High: $5.41 Week Perf: -12.38 %
Day's Low: $ 4.60 30 Day Perf: -49.31 %
Volume (M): 25 52 Wk High: $ 44.80
Volume (M$): $ 115 52 Wk Avg: $16.75
Open: $5.05 52 Wk Low: $4.60



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 0
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Bio Path Holdings Inc
Bio-Path Holdings Inc. is a clinical-stage biotechnology company that focuses on developing therapeutic products to treat cancer and other diseases. It is headquartered in Houston, Texas. The company's proprietary technology platform, known as DNAbilize, uses synthetic oligonucleotides to deliver cancer-fighting drugs directly to cancer cells. This targeted approach is designed to enhance the effectiveness of the drugs while minimizing side effects. Bio-Path Holdings has a pipeline of drug candidates in various stages of development, targeting different types of cancer, including acute myeloid leukemia and solid tumors. The company is committed to advancing innovative treatments for patients with unmet medical needs in the oncology field.


   Company Address: 4710 Bellaire Boulevard, Suite 210 Bellaire 77401 TX
   Company Phone Number: 742-1357   Stock Exchange / Ticker: NASDAQ BPTH
   BPTH is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Bio Path Holdings Inc

Bio-Path Holdings Inc Sees Improved Operating Shortfall in Fourth Quarter Results

The recent financial results of Bio-Path Holdings Inc, a major player in the pharmaceutical industry, have shed some light on the company's performance in the fourth quarter of 2023, and the implications for its future.
One significant observation from these financial results is the operating shortfall of $-3.033 million in the October to December 31, 2023 quarter. Although the company has not mentioned any revenue for the same period, it is worth noting that this operating shortfall is an improvement compared to the fourth quarter of 2022, where the shortfall was $-3.986 million. This indicates that Bio-Path Holdings Inc has become more efficient in conducting its business operations.

Clinical Study

Breaking Through the Leukemia Barrier: Bio-Path Holdings' Promising Leap with BP1002 RNAi Therapy

Published Thu, Dec 14 2023 12:00 PM UTC


Bio-Path Holdings, a promising cancer therapeutics company, has successfully completed the first dose cohort for its ongoing Phase 1/1b clinical trial of BP1002. This innovative drug, devised to treat refractory/relapsed Acute Myeloid Leukemia (AML), is demonstrating the broad and untapped potential for RNA interference (RNAi) therapies in combating drug-resistant malig...

Bio Path Holdings Inc

Bio Path Holdings Inc Demonstrates Signs of Resilience with Improved Operating Shortfall in Fiscal Third Quarter of 2023

Interpreting the Financial Results of Bio Path Holdings Inc: A Struggle to Attain the Next Stage
As the reporting season for July to September 2023 progresses, several companies in the Major Pharmaceutical Preparations sector have announced their financial results. Among them, Bio Path Holdings Inc stands out with its operating shortfall of $-3.276 million for the third quarter of 2023. This figure is a slight improvement from the operating shortfall of $-3.546 million in the same quarter of the previous year, indicating signs of resilience for the company.
Bio Path Holdings Inc is one of the evolving companies in the pharmaceutical industry, continuously working to enhance its business model. In an environment where competition is fierce and economic viability is crucial, the ability to adapt and achieve the next stage becomes increasingly relevant. Over the most recent fiscal period, the company's executives have managed the resources more efficiently and reduced the diminishing returns to $-3.199 million.

Bio Path Holdings Inc

Business Expenses Surge at Bio Path Holdings Inc During April-June 2023, While Prospect for Revenue Growth Remains Uncertain

Bio Path Holdings Inc, a major player in the Major Pharmaceutical Preparations sector, has recently reported its earnings for the second quarter of 2023. Despite being overshadowed by leaders in the industry, the company's shareholders are hopeful for new revenue sources to emerge in the near future. However, the markets have shown less interest in the company's productivity improvement thus far.
In the April to June 30, 2023 interval, Bio Path Holdings Inc incurred an operating loss of $-4.242 million, a significant increase from the $-3.008 million loss in the corresponding quarter of the previous year. This widening net loss of $-4.234 million, combined with the absence of top-line growth, highlights the challenges the company is currently facing.

Bio Path Holdings Inc

Major Pharmaceutical Preparations Company Faces Operating Shortfall in First Quarter of 2023

Bio Path Holdings Inc is a biosciences company that specializes in the development of targeted therapies for cancerous tumors. As the healthcare sector continues to grow and evolve, Bio Path Holdings Inc has become a major player in the field, with investors looking to the company for its latest earnings, developments, and revenue sources.
In January to March 31, 2023, Bio Path Holdings Inc's quarterly earnings report showed no modifications in revenue, disappointing investors who expected higher returns. Instead, they observed an operating shortfall of $-5.292 million. This shortfall increased in the most recent approaching cycle, as shareholders await new revenue sources that can help the company evolve as soon as possible.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com